{'fraction_non_alphanumeric': 0.0315059861373661, 'fraction_numerical': 0.05356017643352237, 'mean_word_length': 4.8597785977859775, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Clinical Comparison in Finland of Two Oral Contraceptives Containing 0.150 mg Desogestrel in Combination with 0.020 mg Or 0.030 mg Ethinylestradiol

The results of two open Finnish multicenter studies on the effects of two oral contraceptive combinations containing 0.150 mg desogestrel+0.030 mg ethinylestradiol (EE) and 0.150 mg desogestrel+0.020 mg EE respectively were comparatively evaluated, paying particular attention to efficacy, cycle control and tolerance. The two trials were carried out by 20 independent investigators and comprised a total of 270 women, 91 of whom used the 0.150/0.030 mg desogestrel/EE combination for a total of 964 cycles in one trial and 179 the 0.150/0.020 mg desogestrel/EE combination for a total of 2096 cycles in the other trial. In addition the ovulation inhibiting effect of the combination with 0.020 mg EE (based on serum levels of LH, progesterone and 17β‐estradiol) was studied in 5 healthy fertile women. No pregnancies occurred in this study. Both combinations showed a good cycle control and were well tolerated. There were no marked differences between the two preparations with respect to bleeding patterns, body weight, side effects, or drug related drop‐outs. The good efficacy of the lowest estrogen‐dose combination was substantiated by the results of the hormone determinations: all 5 volunteers displayed an anovulatory treatment cycle. It is concluded that despite its lower estrogen content, the clinical use of the 0.150/0.020 mg desogestrel/EE combination is as good as that of the 0.150/0.030 mg desogestrel/EE combination.